SK166097A3 - C-4'-modified adenosine kinase inhibitors - Google Patents
C-4'-modified adenosine kinase inhibitors Download PDFInfo
- Publication number
- SK166097A3 SK166097A3 SK1660-97A SK166097A SK166097A3 SK 166097 A3 SK166097 A3 SK 166097A3 SK 166097 A SK166097 A SK 166097A SK 166097 A3 SK166097 A3 SK 166097A3
- Authority
- SK
- Slovakia
- Prior art keywords
- phenyl
- amino
- compound
- phenylamino
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/486,161 US5674998A (en) | 1989-09-15 | 1995-06-07 | C-4' modified adenosine kinase inhibitors |
PCT/US1996/010404 WO1996040705A1 (en) | 1995-06-07 | 1996-06-07 | C-4' modified adenosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SK166097A3 true SK166097A3 (en) | 1999-06-11 |
Family
ID=23930844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1660-97A SK166097A3 (en) | 1995-06-07 | 1996-06-07 | C-4'-modified adenosine kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
US (1) | US5674998A (de) |
EP (1) | EP0832091B1 (de) |
JP (1) | JPH11507387A (de) |
KR (1) | KR19990022740A (de) |
CN (1) | CN1190401A (de) |
AP (1) | AP9701165A0 (de) |
AT (1) | ATE257841T1 (de) |
AU (1) | AU6178396A (de) |
BG (1) | BG102163A (de) |
BR (1) | BR9609013A (de) |
CA (1) | CA2220642A1 (de) |
CZ (1) | CZ392797A3 (de) |
DE (1) | DE69631330T2 (de) |
EA (1) | EA199800009A1 (de) |
HU (1) | HUP9802193A3 (de) |
IL (1) | IL122335A0 (de) |
IS (1) | IS4621A (de) |
MX (1) | MX9709859A (de) |
NO (1) | NO975585L (de) |
OA (1) | OA10639A (de) |
PL (1) | PL323904A1 (de) |
SK (1) | SK166097A3 (de) |
TR (1) | TR199701539T1 (de) |
WO (1) | WO1996040705A1 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE159257T1 (de) * | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
DK0836605T3 (da) * | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
CA2381297A1 (en) * | 1999-08-27 | 2001-04-19 | Esmir Gunic | Pyrrolo¬2,3-d|pyrimidine nucleoside analogs |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
DK1212327T3 (da) | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
BR0016415A (pt) * | 1999-12-16 | 2002-12-24 | Alcon Inc | Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico |
DE60134196D1 (de) * | 2000-02-10 | 2008-07-10 | Mitsui Chemicals Inc | Verfahren zur selektiven herstellung eines 1-phosphoryliertem zuckerderivativ-anomers und verfahren zur herstellung von nukleosiden |
US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
US7414036B2 (en) * | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
BRPI0400869B8 (pt) * | 2004-03-02 | 2021-05-25 | Univ Estadual Campinas Unicamp | novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
CA2596424C (en) | 2005-02-04 | 2016-03-29 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
CA2618713A1 (en) * | 2005-08-12 | 2007-02-22 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
WO2007092213A2 (en) | 2006-02-02 | 2007-08-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzyme |
EP2557080A1 (de) | 2006-04-04 | 2013-02-13 | The Regents of The University of California | Verfahren zur Identifizierung von PI3-Kinase-Antagonisten |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン, エルエルシー | キナーゼインヒビターおよび使用方法 |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
KR20120024715A (ko) | 2009-05-14 | 2012-03-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | ((1s,2s,4r)?4?{4?〔(1s)?2,3?디하이드로?1h?인덴?1?일아미노〕?7h?피롤로〔2,3?d〕피리미딘?7?일}?2?하이드록시사이클로펜틸)메틸 설파메이트의 하이드로클로라이드 염 |
WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
EP2637669A4 (de) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclische verbindungen und ihre verwendung |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
AU2012284091B2 (en) | 2011-07-19 | 2015-11-12 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CN103998442B (zh) | 2011-08-29 | 2016-09-14 | 无限药品股份有限公司 | 杂环化合物及其用途 |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
CA3107640A1 (en) | 2011-12-22 | 2013-06-27 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
JP6189948B2 (ja) | 2012-06-29 | 2017-08-30 | ファイザー・インク | LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン |
RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
TWI655199B (zh) | 2013-06-26 | 2019-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
US9862743B2 (en) | 2013-10-11 | 2018-01-09 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016066582A1 (en) | 2014-10-28 | 2016-05-06 | Bci Pharma | Nucleoside kinase inhibitors |
EA201890454A1 (ru) | 2015-08-06 | 2018-07-31 | Чимерикс, Инк. | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP7054681B2 (ja) | 2016-06-24 | 2022-04-14 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 組合せ療法 |
US11111264B2 (en) | 2017-09-21 | 2021-09-07 | Chimerix, Inc. | Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof |
CA3149846A1 (en) | 2019-08-08 | 2021-02-11 | B.C.I. Pharma | Quinoline derivatives as protein kinase inhibitors |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CN117120444A (zh) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | 使用酰胺制备卡巴核苷的方法 |
KR102639275B1 (ko) * | 2021-06-08 | 2024-02-21 | 퓨쳐메디신 주식회사 | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455420A (en) * | 1983-01-13 | 1984-06-19 | Hoffmann-La Roche Inc. | 4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine |
DE3712735A1 (de) * | 1987-04-15 | 1988-11-10 | Boehringer Mannheim Gmbh | Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel |
AU665184B2 (en) * | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
CA2100863A1 (en) * | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
WO1994018215A1 (en) * | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1995
- 1995-06-07 US US08/486,161 patent/US5674998A/en not_active Expired - Fee Related
-
1996
- 1996-06-07 TR TR97/01539T patent/TR199701539T1/xx unknown
- 1996-06-07 CZ CZ973927A patent/CZ392797A3/cs unknown
- 1996-06-07 WO PCT/US1996/010404 patent/WO1996040705A1/en active IP Right Grant
- 1996-06-07 HU HU9802193A patent/HUP9802193A3/hu unknown
- 1996-06-07 CN CN96195383A patent/CN1190401A/zh active Pending
- 1996-06-07 AU AU61783/96A patent/AU6178396A/en not_active Abandoned
- 1996-06-07 CA CA002220642A patent/CA2220642A1/en not_active Abandoned
- 1996-06-07 AP APAP/P/1997/001165A patent/AP9701165A0/en unknown
- 1996-06-07 EA EA199800009A patent/EA199800009A1/ru unknown
- 1996-06-07 EP EP96919442A patent/EP0832091B1/de not_active Expired - Lifetime
- 1996-06-07 IL IL12233596A patent/IL122335A0/xx unknown
- 1996-06-07 JP JP9502290A patent/JPH11507387A/ja not_active Ceased
- 1996-06-07 AT AT96919442T patent/ATE257841T1/de not_active IP Right Cessation
- 1996-06-07 KR KR1019970709182A patent/KR19990022740A/ko not_active Application Discontinuation
- 1996-06-07 DE DE69631330T patent/DE69631330T2/de not_active Expired - Fee Related
- 1996-06-07 BR BR9609013-8A patent/BR9609013A/pt unknown
- 1996-06-07 PL PL96323904A patent/PL323904A1/xx unknown
- 1996-06-07 SK SK1660-97A patent/SK166097A3/sk unknown
-
1997
- 1997-11-26 IS IS4621A patent/IS4621A/is unknown
- 1997-12-03 OA OA70150A patent/OA10639A/en unknown
- 1997-12-03 NO NO975585A patent/NO975585L/no unknown
- 1997-12-08 MX MX9709859A patent/MX9709859A/es unknown
-
1998
- 1998-01-07 BG BG102163A patent/BG102163A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU6178396A (en) | 1996-12-30 |
AP9701165A0 (en) | 1998-01-31 |
ATE257841T1 (de) | 2004-01-15 |
WO1996040705A1 (en) | 1996-12-19 |
TR199701539T1 (xx) | 1998-04-21 |
JPH11507387A (ja) | 1999-06-29 |
DE69631330T2 (de) | 2004-10-28 |
EA199800009A1 (ru) | 1998-06-25 |
KR19990022740A (ko) | 1999-03-25 |
DE69631330D1 (de) | 2004-02-19 |
MX9709859A (es) | 1998-08-30 |
CN1190401A (zh) | 1998-08-12 |
IL122335A0 (en) | 1998-04-05 |
HUP9802193A3 (en) | 1999-10-28 |
PL323904A1 (en) | 1998-04-27 |
BG102163A (en) | 1998-10-30 |
HUP9802193A2 (hu) | 1999-05-28 |
CA2220642A1 (en) | 1996-12-19 |
CZ392797A3 (cs) | 1999-04-14 |
IS4621A (is) | 1997-11-26 |
OA10639A (en) | 2002-09-17 |
US5674998A (en) | 1997-10-07 |
EP0832091B1 (de) | 2004-01-14 |
BR9609013A (pt) | 1999-12-14 |
NO975585L (no) | 1998-02-05 |
EP0832091A1 (de) | 1998-04-01 |
NO975585D0 (no) | 1997-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK166097A3 (en) | C-4'-modified adenosine kinase inhibitors | |
US5763596A (en) | C-4' modified adenosine kinase inhibitors | |
US5763597A (en) | Orally active adenosine kinase inhibitors | |
US5721356A (en) | Orally active adenosine kinase inhibitors | |
US5795977A (en) | Water soluble adenosine kinase inhibitors | |
US5726302A (en) | Water soluble adenosine kinase inhibitors | |
NO180418B (no) | Adenosinkinaseinhibitorer | |
JPH08506343A (ja) | リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質 | |
DE3924424A1 (de) | Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung | |
US5777100A (en) | AICA riboside analogs | |
JP2009102366A (ja) | Aicaリボシド類縁体 | |
US5864033A (en) | Adenosine kinase inhibitors | |
MXPA97009656A (en) | Soluble adenosin kinase inhibitors in a | |
MXPA97009773A (en) | Inhibitors of adenosin cinasa oralmente acti | |
IE920190A1 (en) | Adenosine kinase inhibitors | |
MXPA94000878A (en) | Inhibitors of the adenosin kinase, which include derivatives of lixofurans |